title: Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists.
abstract: The difference in location between the receptor occupancy curve of an agonist and its functional response has been described as receptor reserve. This "reserve" for a specific receptor has been found to differ from tissue to tissue and between agonists acting on the same tissue. Recently, two structurally different neurokinin 1 (NK1) receptor antagonists were taken into human and both were tested as antidepressants and for insomnia. Vestipitant and Casopitant both have high affinity for the human NK1 receptor (pKi = 9.4 and 10.2, respectively). In human, at the chosen clinical doses, receptor occupancy was measured in the frontal cortex, at 24 hours post administration, as ∼90% for vestipitant (15 mg) and ∼100% for casopitant (30 mg). In patients with moderate to severe major depression, vestipitant given at 15 mg for 8 weeks showed no statistical significant benefit as measured by change in baseline in HAM-D total score; whereas casopitant at 80 mg achieved statistically significant improvement versus placebo at week 8 (LOCF HAMD17 = -2.7, p = 0.023). A lower dose of 30 mg showed a clear but not significant separation from placebo. However, in acute studies in insomnia, both vestipitant and casopitant at 15 mg and 30 mg, respectively, significantly reduced latency to persistent sleep, wakenings after sleep onset and increased total sleep time by similar amounts. These clinical results suggest that for major depression the receptor occupancy of an NK1 antagonist needs to be very high (almost 100%), whereas, for insomnia a lower occupation is sufficient to give clinical effect.
authors.affiliation: Analytical Pharmacologist , San Bonifacio , Italy .
authors.forename: David G
authors.initials: DG
authors.lastname: Trist
authors.forename: Emiliangelo
authors.initials: E
authors.lastname: Ratti
authors.forename: Alan
authors.initials: A
authors.lastname: Bye
mesh_terms: D000928:Antidepressive Agents / Q000008:administration & dosage; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000503:physiopathology; D005464:Fluorobenzenes / Q000008:administration & dosage*; D006801:Humans; D064729:Neurokinin-1 Receptor Antagonists / Q000008:administration & dosage / Q000378:metabolism; D010879:Piperazines / Q000008:administration & dosage*; D010880:Piperidines / Q000008:administration & dosage*; D018040:Receptors, Neurokinin-1 / Q000378:metabolism*; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy* / Q000503:physiopathology; D014018:Tissue Distribution; D014508:Urea
chemical_list: D000928:Antidepressive Agents; D005464:Fluorobenzenes; D064729:Neurokinin-1 Receptor Antagonists; D010879:Piperazines; D010880:Piperidines; D018040:Receptors, Neurokinin-1; C531951:casopitant; D014508:Urea; C534550:vestipitant